In recent years, the country has promulgated centralized bulk-buying policy for high value medical consumables in the field of medical devices.

According to the network statistics, market size of China’s blood group reagent was RMB 2.55 billion in 2024, which is expected to achieve RMB 2.86 billion in 2025 with growth rate of 12.3%.

It is foreseeable that development trend of Blood typing reagent technologies is mainly reflected by improvement of Blood typing accuracy, increase in Blood typing efficiency and reduction of test time; improvement of Blood typing sensitivity and prevention of missed test; evaluation of antibody titer determination and other aspects.

At present, MGT-based blood group test card has been used extensively in the field of blood typing, and MGT boasts of easy operation, high sensitivity, accurate results that can be saved and other strengthens, which allowed it to become method recommended by American Association of Blood Banks (AABB), technique recognized by FDA and internationally recognized blood group analysis test technique.

At present, domestic blood typing reagent-related products already covered ABO blood typing, test of Rh and other irregular antibodies, and anti-human globulin test.

Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Blood typing reagents mainly refer to reagents and kits used separately or in combination with blood grouping analyzer, which belong to a segment of in vitro diagnostic (IVD) reagent industry.

Blood typing-related products mainly include two sectors of blood typing instruments and blood typing reagents.

Recently, an outbreak of Nipah virus occurred in West Bengal, India, with 5 confirmed cases reported, including several healthcare workers. Nearly 100 people have been placed under home quarantine, and one patient is in critical condition, highlighting the urgency of epidemic control.

Synthego, a recognized leader in CRISPR solutions, announces its formal entry into the molecular and clinical diagnostic reagents sector. Building upon its reputation for rigorous quality, custom manufacturing, and innovation, Synthego's significant expansion of its product portfolio empowers researchers, clinicians, and diagnostic laboratories with high-quality, reliable reagents designed to accelerate the development and deployment of cutting-edge diagnostic tests.